Despite having prototypes ready, the world’s second-largest PC maker Acer Inc (宏碁) yesterday said it would not rush onto the e-reader bandwagon for now, as it was still studying the feasibility of a successful business model and a total product solution.
The size of the e-reader market is not that big and the industry has yet to come up with a proven business model, Acer chairman Wang Jeng-tang (王振堂) told reporters yesterday.
Acer is watching whether the public would embrace e-readers and from a profitability standpoint, the company is not ready to launch e-readers, despite having the hardware ready, Wang said.
Last month, electronics maker BenQ Corp (明基) and publisher Yuan-Liou Publishing Co (遠流出版) debuted e-readers in Taipei.
Meanwhile, Acer is expecting a decrease in notebook shipments this quarter of 5 percent, from the earlier projected 10 percent decrease.
New laptop products in the pipeline include a less than 2cm-thick consumer ultra-low voltage (CULV) model, and another running on Intel Corp’s next generation of Core microprocessors.
Wang said the inferior computing power of CULV models has been holding them back, but that the new Core processors would resolve the issue by offering better computation as well as a long-lasting battery life.
The company projects that the commercial PC segment will see an upturn starting in the second half of the year, especially in emerging markets such as Brazil, Russia, India, China and Indonesia.
MOVING ON UP: Taiwan improved in all four areas measured by the IMD, making its biggest leap, from 17th to sixth place, in economic performance Taiwan moved up three spots from last year to place eighth, its best performance since 2013, in the latest annual world competitiveness rankings, released yesterday by the International Institute for Management Development (IMD). Innovation, digitalization, welfare benefits and social cohesion are critical to economic performance, with Switzerland, Sweden, Denmark, the Netherlands and Singapore making up the top five on the list this year, the Switzerland-based institute said, after grading 64 countries and regions based on economic performance, infrastructure, and government and business efficiency. “Leading performers are characterized by varying degrees of investment in innovation, diversified economic activities and supportive public policy,” IMD
With the US opening up to travel, demand in Taiwan for US-bound flights has soared, pushing up ticket prices to most destinations in North America, tourism sources said. Fares for destinations in the US have risen dramatically since the middle of last month, and the trend is expected to continue in the coming months, as California on Tuesday lifted most social distancing and capacity limits put in place to contain the spread of COVID-19, ezTravel Co (易遊網) said in a statement yesterday. The travel agency forecast that the number of tickets sold this month is likely to be double or triple
‘MATTER OF SURVIVAL’: Vice Premier Liu He is to lead the development of ‘third-generation’ chips, a field not yet dominated by any nation or company Chinese President Xi Jinping (習近平) is renewing his years-long push to achieve technology self-sufficiency by tapping a top deputy to shepherd a key initiative aimed at helping domestic chipmakers overcome US sanctions. Chinese Vice Premier Liu He (劉鶴), Xi’s economic czar whose sprawling portfolio spans trade to finance and technology, has been tapped to spearhead the development of so-called “third-generation” chip development and capabilities, and is leading the formulation of a series of financial and policy supports for the technology, people with knowledge of the matter said. It is a nascent field that relies on newer materials and gear beyond traditional silicon,
OPPORTUNITY: The company aims to sell its product soon, as enterovirus vaccines are not available anywhere but China, where firms are only marketing their vaccines locally Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations. The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday. Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said. The company enrolled its first participant for